Vulcan Energy Resources (ASX: VUL)

The US Food and Drug Administration (FDA) has given the green light to respiratory imaging technology company 4DMedical (ASX: 4DX) for its CT-based lung ventilation analysis product (CT LVAS™). This FDA clearance will allow 4DMedical to leverage the US’s available CT hardware and boost its presence in the region. The FDA clearance follows the rollout

Back in the 1970s the world marvelled as the then revolutionary CT scan and nuclear medicine technologies that allowed health care professionals to gain never-before-seen insights into patients’ diseased lungs. The 3D pictures they provided were high resolution images that were a vast improvement on the 2D (x-rays) and 1D (spirometry) tests previously available. Fast

Unfortunately, COVID seems to be here to stay, with re-infections becoming the new norm, and people dropping like flies. (I, of course, being of superior birth, am yet to contract the spicy flu, but time will tell.) The pandemic saw growth in a few industries like eCommerce, however an interesting subset of pandemic profiteers emerged,

Australians are a smart bunch. Although the pavlova is disputed, we gladly claim awesome inventions like the black box flight recorder, spray-on skin, the cochlear implant, plastic money and fairy bread (arguably the greatest invention of them all). Whilst I’m not sure much could compete with fairy bread, 4DMedical (ASX: 4DX) are giving it a

While we are seemingly on the back-stretch of the COVID-19 pandemic, increased medical awareness has changed how we diagnose respiratory diseases with medtech company 4DMedical (ASX: 4DX) leading the charge. Their proprietary FDA/TGA approved, patented respiratory imaging platform, XV Technology turns sequences of x-ray images into four-dimensional, quantitative data to improve and accelerate diagnostic accuracy.

Investors that missed out on the IPO for medtech company 4D Medical (ASX: 4DX) have had no qualms buying the stock on market with shares in 4DX opening at $1.47 when trading commenced this morning, more than double the IPO Offer Price of $0.73.  The significant jump follows a similar trend among Australian investors that